Tanja Obradovic
May 13, 2025, 17:33
Tanja Obradovic: AI Advancing Novel Cancer Drug Design and Patient Outcomes
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Great advances in using artificial intelligence (AI) for the novel cancer drug design are here and possibility to improve outcomes in patients is rising.
Innovative Biotech using AI cancer drug discovery platform Lantern Pharma Inc. (Nasdaq: LTRN) RADR, just announced that the FDA has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in non-small cell lung cancer (NSCLC) patients.
Study will target patients with very high unmet need with KEAP1 and/or STK11 mutations positivity and low expression of PD-L1 and LP-184 will be tested in combination with the immune checkpoint inhibitor therapies-nivolumab and ipilimumab.
LP-184 is a small-molecule drug candidate with a synthetically lethal mechanism of action (MoA) that preferentially damages DNA in cancer cells that harbor mutations in DNA damage repair (DDR) genes and that overexpress the enzyme PTGR1. LP-184 Phase 1 for monotherapy dose escalation in solid tumors is already ongoing (NCT05933265) and this news adds great possibilities for future pipeline expansion.”
More posts featuring Tanja Obradovic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 13, 2025, 17:33
May 13, 2025, 17:21
May 13, 2025, 16:52
May 13, 2025, 15:33
May 13, 2025, 15:20